Maze Therapeutics exec sells 16K shares after option exercise
Maze Therapeutics’ President, R&D & CMO reported a Rule 10b5-1 option exercise, share sale, and RSU vesting and settlement on September 1, 2026.
Rhea-AI Filing Summary
Maze Therapeutics, Inc. (MAZE) reported that President, R&D & CMO Harold Bernstein exercised stock options and restricted stock units and sold shares on September 1, 2026 pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025. He exercised options for 16,141 shares of common stock at an exercise price of $10.42 per share, received 16,141 shares of common stock, and sold those 16,141 shares at a weighted average price of $26.3622 per share in multiple trades between $26.11 and $26.64. He also converted 20,000 restricted stock units into 20,000 shares of common stock and continues to hold 20,000 restricted stock units that vest in two equal installments on September 1, 2026 and September 1, 2027, all reported as directly owned.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
5 txns
Insider
Bernstein Harold
Role
President, R&D & CMO
Sold
16,141 shs ($426K)
Approx. gross sale proceeds
$426K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F3 | 16,141 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F4, F5, F6 | 20,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 16,141 | $10.42 | $168K |
| Sale | Common Stock F1, F2 | 16,141 | $26.3622 | $426K |
| Exercise | Common Stock | 20,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 160,662 contracts (Direct);
Restricted Stock Units — 20,000 contracts (Direct);
Common Stock — 20,000 shares (Direct)
Footnotes (6)
- F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $26.64 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
- F4. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
- F5. The award vested or vests as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date.
- F6. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.
Key Figures
Options exercised: 16,141 shares
Option exercise price: $10.42 per share
Shares sold: 16,141 shares
+5 more
8 metrics
Options exercised
16,141 shares
Stock options exercised into Maze Therapeutics common stock on September 1, 2026
Option exercise price
$10.42 per share
Exercise price for the 16,141 stock options converted into common stock
Shares sold
16,141 shares
Common shares sold on September 1, 2026 following option exercise
Weighted average sale price
$26.3622 per share
Weighted average price for 16,141 Maze Therapeutics shares sold in multiple trades
Sale price range
$26.11–$26.64 per share
Price range of the multiple transactions included in the reported sale
RSUs converted
20,000 restricted stock units / 20,000 shares
RSUs representing rights to receive Maze Therapeutics common stock and corresponding shares acquired
Remaining options
160,662 options
Stock options reported as directly owned after the 16,141-share option exercise
RSU vesting dates
September 1, 2026 and September 1, 2027
Two vesting dates for the reported restricted stock unit award, subject to continued service
Key Terms
Rule 10b5-1 trading plan, restricted stock unit, weighted average price, beneficial ownership
4 terms
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock unit financial
"Each restricted stock unit represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
weighted average price financial
"The reported price in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership regulatory
"The reporting person undertakes to provide to the Issuer, any security holder"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What transactions did MAZE executive Harold Bernstein report on this Form 4?
He reported exercising options for 16,141 shares of Maze Therapeutics common stock, selling 16,141 shares in open-market transactions, and settling 20,000 restricted stock units into 20,000 shares of common stock on September 1, 2026.
Were the MAZE transactions made under a Rule 10b5-1 trading plan?
Yes. A footnote states the transactions marked with that footnote were effected pursuant to a Rule 10b5-1 trading plan adopted by Harold Bernstein on September 29, 2025. The filing-level checkbox also affirms Rule 10b5-1 plan status.
What did the MAZE restricted stock unit transaction involve?
Bernstein reported 20,000 restricted stock units, each representing a contingent right to receive one share of MAZE common stock. 20,000 shares of common stock were acquired, and the award vests in two installments: September 1, 2026 and September 1, 2027, subject to continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
